Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.

Fei XuGuangjian YangHai-Yan Xu Lu YangWeini QiuYan Wang

Published in: Thoracic cancer (2020)

Chemotherapy achieved better outcomes than afatinib for Chinese HER2 mutated advanced NSCLC patients, especially for the most common subtype, YVMA insertions.

Keyphrases

advanced non small cell lung cancer
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
small cell lung cancer
epidermal growth factor receptor
type diabetes
adipose tissue
insulin resistance
patient reported
locally advanced
chemotherapy induced